Adamis resubmits new drug application to FDA for anaphylaxis treatment
Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A
Commercial Banking: June 22nd Edition
Understanding Loss Given Default A Review of Three Approaches
Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy
Adamis Pharmaceuticals Corp. resubmitted a new drug application to the U.S. FDA for epinephrine prefilled syringe product candidate for the emergency treatment of anaphylaxis, an extreme and severe allergic reaction.
The resubmission seeks to address issues raised by the agency in its June complete response letter.